Study of Allogenic Adipose-derived Stem Cells in Crohn's Fistula — ALLO-ASC

Crohn Clinical Trial

Official title:
Phase I Study of Dose Escalation of Human Allogenic Adipose-derived Stem Cells (ALLO-ASC) to Evaluate Safety and Efficacy in Patients With Crohn's Fistula

Status Completed

Clinical Trial Summary

Adipose-derived stem cells have properties of differentiation to various types of cells, immunomodulatory effects. adipose-derived stem cells (ASCs) show also low immunogenicity. Anterogen has developed ANTG-ASC(Autologous ASC) which has shown good efficacy and safety in Phase I and II study on the patients with Crohn's fistula. However, Crohn's patients are sometimes not fat enough to extract fat tissue for culturing ASCs. Therefore the investigators have planned to study allogenic ASCs for safety and efficacy in patients with Crohn's fistula.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01440699
Study type	Interventional
Source	Anterogen Co., Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	September 2011
Completion date	November 8, 2012

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02842450` - Study of Photographs of Interest in Training to Obtain Good Reproducibility of the Diagnosis of Perianal Lesions of Crohn's Disease Inspection in Internal Gastroenterology	N/A